

NOVEL MURINE POLYNUCLEOTIDE SEQUENCES AND MUTANT CELLS  
AND MUTANT ANIMALS DEFINED THEREBY

The present application claims priority to U.S. Provisional Appl. Ser. No. 60/237,272 which was filed October 2, 2000. The present application incorporates by reference U.S. Applications Ser. No. 08/728,963, 60/109,302, 09/276,533 and U.S. Patent Numbers 6,080,576, 6,136,566, 6,139,833 and their respective disclosures in their entirety.

10

1.0. FIELD OF THE INVENTION

The present invention is in the field of molecular genetics. The application discloses novel nucleic acid sequences that: each define the locus of a corresponding mutated murine embryonic stem cell clone; partially define the scope of exons that can be trapped and identified by the disclosed vectors/methods; and that are also useful, *inter alia*, for identifying the coding regions of the murine genome.

20

2.0. BACKGROUND OF THE INVENTION

Most mammalian genes are divided into exons and introns. Exons are the portions of the gene that are spliced into mRNA and encode the protein product of a gene. In genomic DNA, these coding exons are divided by non-coding intron sequences. Although RNA polymerase transcribes both intron and exon sequences, the intron sequences must be removed from the transcript so that the resulting mRNA can be translated into protein. Accordingly, all mammalian, and most eukaryotic, cells have the machinery to splice exons into mRNA.

Gene trap vectors have been designed to integrate into introns or genes in a manner that allows the cellular splicing machinery to splice vector encoded exons to cellular mRNAs. Commonly, gene trap vectors contain selectable marker sequences that are preceded by strong splice acceptor sequences and are not preceded by a promoter. Thus, when such vectors integrate into a gene, the cellular splicing machinery splices exons from the trapped gene onto the 5' end of the selectable marker sequence. Typically, such selectable marker

TO9260-662560

genes can only be expressed if the vector encoding the gene has integrated into an intron. The resulting gene trap events are subsequently identified by selecting for cells that can survive selective culture.

5 Gene trapping has generally proven to be an efficient method of mutating large numbers of genes. The insertion of the gene trap vector creates a mutation in the trapped gene, and also provides a molecular tag for ease of identifying the gene that has been trapped. When ROSA $\beta$ geo was used to trap 10 genes it was demonstrated that at least 50% of the resulting mutations resulted in a phenotype when examined in mice. This indicates that the gene trap insertion vectors are useful mutagens. Although a powerful tool for mutating genes, the potential of the method has historically been limited by the 15 difficulty in identifying the trapped genes. Methods that have been used to identify trap events rely on the fusion transcripts resulting from the splicing of exon sequences from the trapped gene to sequences encoded by the gene trap vector. Common gene identification protocols used to obtain sequences 20 from these fusion transcripts include 5' RACE, cDNA cloning, and cloning of genomic DNA surrounding the site of vector integration. However, these methods have proven labor intensive, not readily amenable to automation, and generally impractical for high-throughput.

25 More recently, vectors have been developed that rely on a new strategy of gene trapping that uses a vector that contains a selectable marker gene preceded by a promoter and followed by a splice donor sequence instead of a polyadenylation sequence. These vectors do not provide selection unless they 30 integrate into a gene and subsequently trap downstream exons that provide a polyadenylation sequence. Integration of such vectors into the chromosome results in the splicing of the selectable marker gene to 3' exons of the trapped gene. These vectors provide a number of advantages. They can be used to 35 trap genes regardless of whether the genes are normally expressed in the cell type in which the vector has integrated. In addition, cells harboring such vectors can be screened

using automated (e.g., 96-well plate format) gene identification assays such as 3' RACE (see generally, Frohman, 1994, PCR Methods and Applications, 4:S40-S58). Using these vectors it is possible to produce large numbers of mutations and rapidly identify the mutated, or trapped, gene by DNA sequence analysis.

### 3.0. SUMMARY OF THE INVENTION

The subject invention provides numerous isolated and purified mammalian, particularly murine, cDNAs produced using gene trap technology. The OMNIBANK gene trapped sequences (GTSS) of the subject invention are disclosed as SEQ ID NOS: 1-1,000 in the appended Sequence Listing.

The subject invention contemplates the use of one or more of the subject GTSS, or portions thereof, to isolate cDNAs, genomic clones, or full-length genes/polynucleotides, or homologs, heterologs, paralogs, or orthologs thereof, that are capable of hybridizing to one or more of the disclosed GTSS under stringent conditions.

The subject invention additionally contemplates methods of analyzing biopolymer (e.g., oligonucleotides, polynucleotides, oligopeptides, peptides, polypeptides, proteins, etc.) sequence information comprising the steps of loading a first biopolymer sequence into or onto an electronic data storage medium (e.g., digital or analogue versions of electronic, magnetic, or optical memory, and the like) and comparing said first sequence to at least a portion of one of the polynucleotide sequences, or amino acid sequences encoded thereby, that is first disclosed in, or otherwise unique to, SEQ ID NOS:1-1,000. Typically, the polynucleotide sequences, or amino acid sequences encoded thereby, will also be present on, or loaded into or onto a form of electronic data storage medium, or transferred therefrom, concurrent with or prior to comparison with the first polynucleotide.

Another embodiment of the claimed invention is the use of an oligonucleotide or polynucleotide sequence first disclosed in at least a portion of at least one of the GTS sequences of

SEQ ID NOS: 1-1,000 as a hybridization probe. Of particular interest is the use of such sequences in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates,  
5 crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (i.e., gene chips, microtiter plates, etc.) of polynucleotides wherein at least one of the polynucleotides on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence  
10 first disclosed in at least one of the GTS sequences of SEQ ID NOS: 1-1,000. Moreover, an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS: 1-1,000 can be incorporated into a phage display system that can be used to screen for proteins, or  
15 other ligands, that are capable of binding an amino acid sequence encoded by an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS: 1-1,000.

An additional embodiment of the present invention is a library comprising individually isolated linear DNA molecules corresponding to at least a portion of the described GTSs that are useful for synthesizing physically contiguous sequences of overlapping related GTSs by, for example, the polymerase chain reaction (PCR).

25 The subject invention also provides for an oligonucleotide hybridization probe comprising sequence that is identical or complementary to a portion of a sequence that is first disclosed in, or preferably unique to, at least one of the GTS polynucleotides in the appended Sequence Listing.  
30 The oligonucleotide probes will generally comprise between about 8 nucleotides and about 80 nucleotides, preferably between about 15 and about 40 nucleotides, and more preferably between about 20 and about 35 nucleotides.

The subject invention also provides for an antisense  
35 molecule that comprises at least a portion of sequence that is first disclosed in, or preferably unique to, at least one of the GTS polynucleotides.

The subject invention also contemplates a purified polypeptide in which at least a portion of the polypeptide is encoded by, and thus first disclosed by, at least a portion of a GTS of the present invention.

5 The subject invention further contemplates a mutated ES cell, or a mutated cell, tissue, or animal derived therefrom, that stably incorporates a gene trap vector into a specifically identified gene or a gene comprising one or more of the disclosed GTS polynucleotide sequences.

10 In summary, the unique sequences described in SEQ ID NOS:1-1,000 are useful for the identification of coding sequence and the mapping of a unique gene to a particular chromosome. These novel sequences can also be used in addressable arrays, such as gene chips, to identify and 15 characterize temporal and tissue specific gene expression. When the unique sequences described in SEQ ID NOS:1-1,000 are expressed in mouse embryonic stem cells ("ES cells"), these novel sequences provide a method of identifying phenotypic expression of particular genes as well as a method of 20 assigning function to previously unknown genes. The unique sequences described in SEQ ID NOS:1-1,000 can be further used to identify the gene of interest from many sources including, but not limited to, libraries consisting of cDNA or genomic clones and for the *in silico* screening of nucleic acid and 25 protein databases. Additionally, SEQ ID NOS: 1-1,000 can be incorporated into a phage display system and used to screen for proteins, or other ligands. The unique sequences described in SEQ ID NOS:1-1,000 have further utility for 30 genetic manipulations such as antisense inhibition and gene targeting.

#### 4.0. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES

The Sequence Listing is a compilation of nucleotide sequences obtained by sequencing a gene trap library that at 35 least partially identifies the genes in the target cell genome that can be trapped by the described gene trap vectors (i.e., the repertoire of genes that are active, or have not been

inactivated, with the tested ES cell population). The Sequence Listing was prepared using the conventions described in the 1996 edition of the 37 C.F.R. sections 1.801-1.825, and/or WIPO Standard ST.25 as referenced by the 1999 edition of 37 C.F.R. sections 1.801-1.825

5 Figures 1A-1C present a diagrammatic representation of representative gene trap vectors used to generate the described sequences.

10 5.0. DETAILED DESCRIPTION OF THE INVENTION

The current invention relates to novel polynucleotides that are expressed in mouse embryonic stem cells ("ES cells"), and which provide unique tools for gene discovery, diagnostic gene expression analysis, cross species hybridization

15 analysis, and for genetic manipulations using a variety of techniques known to those skilled in the art, like, for example, antisense inhibition, gene targeting, etc.

Furthermore, the expression of these novel polynucleotides in ES cells suggests their involvement in developmental and cell 20 differentiation processes, making them good candidates to treat disorders and abnormalities affecting development and cell differentiation.

Additionally, because they are totipotent, the disclosed mutated ES cells (Lex-1 cells from murine strain A129) can be 25 microinjected into blastocysts, introduced to pseudopregnant host animals, and the offspring bred to produce mutated animals as described, for example, in "Mouse Mutagenesis", 1998, Zambrowicz *et al.*, eds., Lexicon Press, The Woodlands, TX, and periodic updates thereof, and U.S. Patent Application

30 Ser. No. 08/943,687, both of which are herein incorporated by reference. Consequently, additional aspects of the subject invention are mutated mammalian, and preferably murine, cells that have been mutated by a process involving the use genetically engineered vectors or nucleotides to alter the

35 naturally occurring function, sequence, or expression of a genetic locus encoding a novel portion of sequence (e.g., an exon, oligonucleotide sequence, splice junction, etc.)

presented in one of the presently described GTSs.

### 5.1. POLYNUCLEOTIDES OF THE PRESENT INVENTION

5 The nucleotide sequences of the various isolated GTSs of the present invention appear in the Sequence Listing as SEQ ID NOS: 1-1,000. Additional embodiments of the present invention are GTS variants, or homologs, paralogs, orthologs, etc., which include isolated polynucleotides, or complements  
10 thereof, that hybridize to one or more of the disclosed GTSs of SEQ ID NOS: 1-1,000 under stringent, or preferably highly stringent, conditions.

By way of example and not limitation, high stringency hybridization conditions can be defined as follows:

15 Prehybridization of filters containing DNA to be screened is carried out for 8 h to overnight at 65°C in a buffer containing 6X SSC, 50mM Tris-HCl (pH 7.5), 1mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in  
20 prehybridization mixture containing 100µg/ml denatured salmon sperm DNA and 5-20 x 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe (alternatively, as in all hybridizations described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used). The filters  
25 are then washed in approximately 1X wash mix (10X wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for 5 minutes each at room temperature, then in 1X wash mix containing 1%  
30 SDS at 60°C (alternatively, as in all washes described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein, approximately, 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and  
35 about 6X can be used in conjunction with a suitable wash temperature) containing 0.1% SDS at 60°C (alternatively,

approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min. The filters are then air dried and exposed to x-ray film for autoradiography. In an alternative protocol, washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Another example of hybridization under highly stringent conditions is hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3).

Additionally contemplated are GTS polynucleotides that are at least about 99, 95, 90, or about 85 percent similar to corresponding regions of one of SEQ ID NOS: 1-1,000 (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using default parameters).

Preferably, such GTS variants will encode at least a portion or domain of a, preferably naturally occurring, protein or polypeptide that encodes a functional equivalent to a protein or polypeptide, or portion or domain thereof, encoded by the disclosed GTSs. Additional examples of GTS variants include polynucleotides, or complements thereof, that are capable of binding to the disclosed GTSs under less stringent conditions, such as moderately stringent conditions (e.g., washing in 0.2xSSC/0.1% SDS at 42° C (Ausubel et al., 1989, *supra*). Moderately stringent conditions can be additionally defined, for example, as follows: Filters containing DNA are pretreated for 6 h at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 x 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 55°C (alternatively, as in all hybridizations

described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used in combination with a suitable concentration of salt).

5 The filters are then washed in approximately 1X wash mix (10X wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for 5 minutes each at room temperature, then in 1X wash mix containing 1% SDS at 60°C (alternatively, as in all washes described herein, 10 approximately, 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all 15 final washes described herein approximately 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a suitable wash temperature) 20 containing 0.1% SDS at 60°C (alternatively, approximately 42, 44, 45, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min. The filters are then air dried and exposed to x-ray film for autoradiography.

In an alternative protocol, washing of filters is done twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for 25 autoradiography.

Other conditions of moderate stringency that may be used are well-known in the art. For example, washing of filters can be done at 37°C for 1 h in a solution containing 2X SSC, 0.1% SDS. Another example of hybridization under moderately stringent conditions is washing in 0.2xSSC/0.1% SDS at 42°C 30 (Ausubel et al., 1989, *supra*). Such less stringent conditions may also be, for example, low stringency hybridization conditions. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, *Proc. Natl. Acad. Sci. USA* 35 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA,

and 500  $\mu$ g/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 $\mu$ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20  $\times 10^6$  cpm  $^{32}$ P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C (alternatively, as in all hybridizations described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used). The filters are then washed in approximately 1X wash mix (10x wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for five minutes each at room temperature, then in 1X wash mix containing 1% SDS at 60°C (alternatively, as in all washes described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein, approximately, 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a suitable wash temperature) containing 0.1% SDS at 60°C (alternatively, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30 min. The filters are then air dried and exposed to x-ray film for autoradiography. In yet another alternative protocol, washing of filters is done for 1.5 h at 55°C in a solution containing 2X SSC, 25mM Tris-HCl (pH 7.4), 5mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are then blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency that may be used are well-known in the art (e.g., as employed for cross-species hybridizations). Preferably, GTS variants identified or isolated using the above methods will also encode a functionally equivalent gene product (i.e., protein, polypeptide, or domain thereof).

encoding or otherwise associated with a function or structure at least partially encoded by the complementary GTS).

Additional embodiments contemplated by the present invention include any polynucleotide sequence comprising a continuous stretch of nucleotide sequence originally disclosed in, or otherwise unique to, any of the GTSs of SEQ ID NOS: 1-1,000 that are at least 8, or at least 10, or at least 14, or at least 20, or at least 30, or at least about 40, and preferably at least about 60 consecutive nucleotides up to about several hundred bases of nucleotide sequence or an entire GTS sequence. Functional equivalents of the gene products of SEQ ID NOS: 1-1,000 include naturally occurring variants of SEQ ID NOS: 1-1,000 present in other species, and mutant variants, both naturally occurring and engineered, which retain at least some of the functional activities of the gene products of SEQ ID NOS: 1-1,000.

The invention also includes degenerate variants of the claimed GTS sequences, and products encoded thereby. The invention further includes GTS derivatives wherein any of the disclosed GTSs, or GTS variants, is linked to another polynucleotide molecule, or a fragment thereof, wherein the link may be either directly or through other polynucleotides of any sequence and of a length of about 1,000 base pairs, or about 500 base pairs, or about 300 base pairs, or about 200 base pairs, or about 150 base pairs, or about 100 base pairs or about 50 base pairs, or less.

The invention also particularly includes polynucleotide molecules, including DNA, that hybridize to, and are therefore the complements of, the nucleotide sequences of the disclosed GTSs. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), highly stringent conditions may refer to, for example, washing in 6xSSC/0.05% sodium pyrophosphate at 37° C (for oligos having 14-base DNA oligos), 48° C (for 17-base DNA oligos), 55° C (for 20-base DNA oligos), and 60°C (for 23-base oligos). Similar conditions are contemplated for RNA oligos

corresponding to a portion of the disclosed GTS sequences.

These nucleic acid molecules may encode or act as antisense molecules to polynucleotides comprising at least a portion of the sequences first disclosed in SEQ ID NOS: 1-1,000 that are useful, for example, to regulate the expression of genes comprising a nucleotide sequence of any of SEQ ID NOS: 1-1,000, and can also be used, for example, as antisense primers in amplification reactions of gene sequences. With respect to gene regulation, such techniques can be used to regulate, for example, developmental processes by inhibiting, enhancing, hindering, or otherwise modulating the expression of genes in target cells, or particularly in embryonic stem cells. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that can be used to regulate gene expression. Optionally, genes or polynucleotides encoding the GTSs can be conditionally expressed.

Still further, such molecules may be used as components of diagnostic methods whereby, for example, the presence of a particular allele of a gene that contains any of the sequences of SEQ ID NOS: 1-1,000 may be detected. Of particular interest is the use of the disclosed GTSs to conduct analysis of single nucleotide polymorphisms (SNPs) in the human genome, or as general or individual-specific forensic markers.

In addition to the nucleotide sequences described above, full length cDNA or gene sequences that contain any of SEQ ID NOS: 1-1,000 present in the same species and/or homologs of any of those genes present in other species can be identified and isolated by using molecular biological techniques known in the art.

In order to clone the full length cDNA sequence from any species encoding the cDNA corresponding to the entire messenger RNA or to clone variant or heterologous forms of the molecule, labeled DNA probes made from nucleic acid fragments corresponding to any of the partial cDNA sequences disclosed herein may be used to screen a cDNA library. For example, oligonucleotides corresponding to either the 5' or 3' terminus

of the cDNA sequence may be used to obtain longer nucleotide sequences. Briefly, the library may be plated out to yield a maximum of about 30,000 pfu for each 150 mm plate.

Approximately 40 plates are

5      incubated at 37° C until the plaques reach a diameter of 0.25 mm or are just beginning to make contact with one another (3-8 hours). Nylon filters are placed onto the soft top agarose and after 60 seconds, the filters are peeled off and floated on a DNA denaturing solution consisting of 0.4N sodium

10     hydroxide. The filters are then immersed in neutralizing solution consisting of 1 M Tris HCl, pH 7.5, before being allowed to air dry. The filters are prehybridized in casein hybridization buffer containing 10% dextran sulfate, 0.5 M NaCl, 50 mM Tris HCl, pH 7.5, 0.1% sodium pyrophosphate, 1%

15     casein, 1% SDS, and denatured salmon sperm DNA at 0.5 mg/ml for 6 hours at 60° C. The radiolabelled probe is then denatured by heating to 95° C for 2 minutes and then added to the prehybridization solution containing the filters. The filters are hybridized at 60° C (alternatively, as in all

20     hybridizations described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 16 hours. The filters are then washed in approximately 1X wash mix (10X wash mix contains 3M NaCl, 0.6M Tris base, and 0.02M EDTA, alternatively, as with

25     all washes described herein, 2X, 3X, 4X, 5X, 6X wash mix, or more, can be used) twice for 5 minutes each at room temperature, then in 1X wash mix containing 1% SDS at 60° C (alternatively, as in all washes described herein, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66,

30     68, 70, or about 72 degrees or more can be used) for about 30 min, and finally in 0.3X wash mix (alternatively, as in all final washes described herein, approximately, 0.2X, 0.4X, 0.6X, 0.8X, 1X, or any concentration between about 2X and about 6X can be used in conjunction with a suitable wash

35     temperature) containing 0.1% SDS at 60° C (alternatively, approximately 42, 44, 46, 48, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, or about 72 degrees or more can be used) for about 30

min. The filters are then air dried and exposed to x-ray film for autoradiography. After developing, the film is aligned with the filters to select a positive plaque. If a single, isolated positive plaque cannot be obtained, the agar plug 5 containing the plaques will be removed and placed in lambda dilution buffer containing 0.1M NaCl, 0.01M magnesium sulfate, 0.035M Tris HCl, pH 7.5, 0.01% gelatin. The phage may then be replated and rescreened to obtain single, well isolated positive plaques. Positive plaques may be isolated and the 10 cDNA clones sequenced using primers based on the known cDNA sequence. This step may be repeated until a full length cDNA is obtained.

It may be necessary to screen multiple cDNA libraries from different sources/tissues to obtain a full length cDNA.

15 In the event that it is difficult to identify cDNA clones encoding the complete 5' terminal coding region, an often encountered situation in cDNA cloning, the RACE (Rapid Amplification of cDNA Ends) technique may be used. RACE is a proven PCR-based strategy for amplifying the 5' end of 20 incomplete cDNAs. 5'-RACE-Ready cDNA synthesized from human fetal liver containing a unique anchor sequence is commercially available (Clontech). To obtain the 5' end of the cDNA, PCR is carried out, for example, on 5'-RACE-Ready cDNA using the provided anchor primer and the 3' primer. A 25 secondary PCR reaction is then carried out using the anchored primer and a nested 3' primer according to the manufacturer's instructions.

Once obtained, the full length cDNA sequence may be 30 translated into amino acid sequence and examined for certain landmarks found in the amino acid sequences encoded by SEQ ID NOS: 1-1,000, or any structural similarities to these disclosed sequences.

The identification of homologs, heterologs, or paralogs 35 of SEQ ID NOS: 1-1,000 in other, preferably related, species can be useful for developing additional animal model systems that are closely related to humans for purposes of drug discovery. Genes at other genetic loci within the genome that

encode proteins that have extensive homology to one or more domains of the gene products encoded by SEQ ID NOS: 1-1,000 can also be identified via similar techniques. In the case of cDNA libraries, such screening techniques can identify clones derived from alternatively spliced transcripts in the same or different species.

Screening can be done using filter hybridization with duplicate filters. The labeled probe can contain at least 15-30 base pairs of the nucleotide sequence presented in SEQ ID NOS: 1-1,000. The hybridization washing conditions used should be of a lower stringency when the cDNA library is derived from an organism different from, or heterologous to,

the type of organism from which the labeled sequence was derived. With respect to the cloning of a mammalian homolog, heterolog, ortholog, or paralog, using probes derived from any of the sequences of SEQ ID NOS: 1-1,000, for example, hybridization can, for example, be performed at 65° C overnight in Church's buffer (7% SDS, 250 mM NaHPO<sub>4</sub>, 2 mM EDTA, 1% BSA). Washes can be done with 2XSSC, 0.1% SDS at 65° C and then at 0.1XSSC, 0.1% SDS at 65° C.

Low stringency conditions are well-known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N.Y.; and Ausubel *et al.*, 1989, *supra*.

Alternatively, the labeled nucleotide probe of a sequence of any of SEQ ID NOS: 1-1,000 may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions. The identification and characterization of human genomic clones is helpful for designing diagnostic tests and clinical protocols for treating disorders in human patients that are known or suspected to be linked to disease or other development or cell differentiation disorders and abnormalities. For example, sequences derived from regions adjacent to the intron/exon boundaries of the

human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics.

5        Further, gene homologs can also be isolated from nucleic acid of the organism of interest by performing PCR using two oligonucleotide primers derived from SEQ ID NOS: 1-1,000, or two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the gene products encoded 10 by SEQ ID NOS: 1-1,000. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines, cell types, or tissues, like, for example, ES cells from the organism of interest.

15      The PCR product may be sequenced directly or subcloned and sequenced to ensure that the amplified sequences represent the sequences of the gene of interest corresponding to the sequence of SEQ ID NOS: 1-1,000. The PCR fragment may then be used to isolate a full length cDNA clone by a variety of 20 methods. For example, the amplified fragment may be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

25      PCR technology may also be utilized to isolate full length cDNA sequences. For example, RNA may be isolated, following standard procedures, from an appropriate cellular source (i.e., one known, or suspected, to express the gene of interest corresponding to the sequence of SEQ ID NOS: 1-1,000, 30 such as, for example, ES cells). A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" with guanines, for 35 example, using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a poly-C primer. Thus, cDNA

sequences upstream from the amplified fragment may easily be isolated. For a review of cloning strategies that may be used, see e.g., Sambrook et al., 1989, *supra*. Alternatively, cDNA or genomic libraries can be screened using 5' PCR primers that hybridize to vector sequences and 3' PCR primers specific to the gene of interest. Typically, such primers comprise oligonucleotide "priming" sequences first disclosed in, or otherwise unique to, one of the GTSs of SEQ ID NOS: 1-1,000.

The sequence of a gene corresponding to any of the sequences of SEQ ID NOS: 1-1,000 can also be used to isolate mutant alleles of that gene. Such mutant alleles may be isolated from individuals either known or suspected to have a genotype that contributes to the disease of interest or other symptoms of developmental and cell differentiation and/or proliferation disorders and abnormalities. Mutant alleles and mutant allele products may then be utilized in the therapeutic and diagnostic programs described below. Additionally, such sequences of any of the genes corresponding to SEQ ID NOS: 1-1,000 can be used to detect gene regulatory (e.g., promoter or promoter/enchanter) defects that can affect development or cell differentiation.

A cDNA of a mutant gene corresponding to any of the sequences of SEQ ID NOS: 1-1,000 can be isolated as discussed above, or, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from cells derived from an individual suspected of carrying a mutant gene corresponding to any of the sequences of SEQ ID NOS: 1-1,000 by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' region of the normal gene. The amplified product can be directly sequenced or cloned into a suitable vector and subsequently subjected to DNA sequence analysis. By comparing the DNA sequence of the mutant allele to that of the normal allele, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from one or more individuals suspected of carrying, or known to carry, a mutant allele corresponding to any of SEQ ID NOS: 1-1,000. Corresponding mutant cDNA libraries can be also constructed using RNA from cell types known, or suspected, to express such mutant alleles. The corresponding normal gene, or any suitable fragment thereof, may then be labeled and used as a probe to identify the corresponding mutant allele in such libraries. Clones containing the mutant gene sequences may then be identified and analyzed by DNA sequence analysis. Additionally, a protein expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a cell type known, or suspected, to express a mutant allele corresponding to any of the sequences of SEQ ID NOS: 1-1,000 from an individual suspected of carrying, or known to carry, such a mutant allele. In this manner, gene products made by the putatively mutant cell type may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the corresponding normal gene product or a portion thereof, as described below in Section 5.4 (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.) Additionally, screening can be accomplished by screening with labeled fusion proteins. In cases where a mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frame shift mutation), a polyclonal set of antibodies to the wild-type gene product are likely to cross-react with the mutant gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well-known to those of skill in the art.

The invention also encompasses nucleotide sequences that  
35 encode mutant isoforms of any of the amino acid sequences  
encoded by the GTSSs of SEQ ID NOS: 1-1,000, peptide fragments  
thereof, truncated versions thereof, and fusion proteins

including any of the above. Such fusion proteins can include, for example, an epitope tag that aids in purification or detection of the resulting fusion protein, or an enzyme, fluorescent protein, luminescent protein that can be used as a marker.

The present invention additionally encompasses (a) RNA or DNA vectors that contain any portion of SEQ ID NOS: 1-1,000 and/or their complements or that encode any of the peptides or proteins encoded thereby; (b) DNA vectors that contain a cDNA that substantially spans the entire open reading frame corresponding to any of the sequences of SEQ ID NOS: 1-1,000 and/or their complements; (c) DNA expression vectors that contain any of the foregoing sequences, or a portion thereof, operatively associated with a regulatory element that directs the expression of the GTS coding sequences in a host cell; and (d) genetically engineered host cells that contain a cDNA that spans the entire open reading frame, or any portion thereof, corresponding to any of the sequences of SEQ ID NOS: 1-1,000 operatively associated with a regulatory element, generally recombinantly positioned either *in vivo* (such as in gene activation) or *in vitro*, that directs the expression of the GTS coding sequences in the host cell. As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include, but are not limited to, the baculovirus promoter, cytomegalovirus hCMV immediate early gene promoter, the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, acid phosphatase promoters, phosphoglycerate kinase (PGK) and especially 3-phosphoglycerate kinase promoters, and yeast alpha mating factor promoters.

Because the described GTSs represent cellular exon sequence that has been recognized and spliced by the cellular splicing machinery, each GTS further identifies at least one

exon and/or exon splice junctions that is useful, and in many cases necessary, for chromosome mapping and the analysis and practical application of genomic DNA sequence data.

5        5.2. PROTEINS AND POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES  
          EXPRESSED IN MOUSE ES CELLS

Peptides and proteins encoded by the open reading frame of mRNAs corresponding to SEQ ID NOS: 1-1,000, polypeptides and peptide fragments, mutated, truncated or deleted forms of those peptides and proteins, and fusion proteins containing any of those peptides and proteins can be prepared for a variety of uses, including, but not limited to, the generation of antibodies, as reagents in diagnostic assays, the identification of other cellular gene products involved in the regulation of development and cellular differentiation of various cell types, like, for example, ES cells, as reagents in assays for screening for compounds that can be used in the treatment of disorders affecting development and cell differentiation, and as pharmaceutical reagents useful in the treatment of disorders affecting development and cell differentiation.

The invention also encompasses proteins, peptides, and polypeptides that are functionally equivalent to those encoded by SEQ ID NOS: 1-1,000. Such functionally equivalent products include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions can be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively

charged (acidic) amino acids include aspartic acid and glutamic acid.

While random mutations can be introduced into DNA encoding peptides and proteins of the current invention (using random mutagenesis techniques well-known to those skilled in the art), and the resulting mutant peptides and proteins tested for activity, site-directed mutations of the coding sequence can be engineered (using standard site-directed mutagenesis techniques) to generate mutant peptides and proteins within the scope of the current invention having increased functionality.

For example, the novel amino acid sequence of peptides and proteins at least partially encoded by the GTSs of the current invention can be aligned with homologs from different species.

Mutant peptides and proteins can be engineered so that regions of interspecies identity are maintained, whereas the variable residues are altered, e.g., by deletion or insertion of an amino acid residue(s) or by substitution of one or more different amino acid residues. In general,

conservative alterations at the variable positions can be engineered in order to produce a mutant form of a peptide or protein of the current invention that retains function, while non-conservative changes can be engineered at these variable positions to alter function. Alternatively, where alteration

of function is desired, deletion or non-conservative alterations of the conserved regions can be engineered. One of skill in the art may easily test such mutant or deleted form of a peptide or protein of the current invention for these alterations in function using the teachings presented herein.

Other mutations to the coding sequences described above can be made to generate peptides and proteins that are better suited for expression, scale up, etc., in the host cells chosen. For example, the triplet code for each amino acid can be modified to conform more closely to the preferential codon usage of the host cell's translational machinery, or, for example, to yield a messenger RNA molecule with a longer half-

life. Those skilled in the art would readily know what modifications of the nucleotide sequence would be desirable to conform the nucleotide sequence to preferential codon usage or to make the messenger RNA more stable. Such information would be obtainable, for example, through use of computer programs, through review of available research data on codon usage and messenger RNA stability, and through other means known to those of skill in the art.

Peptides corresponding to one or more domains (or a portion of a domain) of the proteins described above, truncated or deleted proteins, as well as fusion proteins in which a full length protein described above, a subunit peptide or truncated version is fused to an unrelated protein, are also within the scope of the invention and can be designed by those of skill in the art on the basis of experimental or functional considerations. Such fusion proteins may include, but are not limited to, fusions to an epitope tag, or fusions to an enzyme, fluorescent protein, or luminescent protein, which provide a marker function.

While the peptides and proteins of the current invention can be chemically synthesized (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y.), large polypeptides derived from any of the polynucleotides described above may advantageously be produced by recombinant DNA technology using techniques well-known in the art for expressing genes and/or coding sequences. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook *et al.*, 1989, *supra*, and Ausubel *et al.*, 1989, *supra*. Alternatively, RNA capable of encoding any of the nucleotide sequences described above may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

A variety of host-expression vector systems may be

utilized to express the nucleotide sequences of the invention. Where the peptide or protein to be synthesized is a soluble derivative, the peptide or polypeptide can be recovered from the culture, *i.e.*, from the host cell in cases where the 5 peptide or polypeptide is not secreted, and from the culture media in cases where the peptide or polypeptide is secreted by the cells. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the expressed 10 peptide or protein, but to assess biological activity, *e.g.*, in drug screening assays.

The expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (*e.g.*, *E. coli*, *B. subtilis*) transformed with 15 recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a nucleotide sequence of the current invention, yeast (*e.g.*, *Saccharomyces*, *Pichia*, etc.) transformed with recombinant yeast expression vectors containing a nucleotide sequence of the current invention, 20 insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing a nucleotide sequence of the current invention, plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with 25 recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing a nucleotide sequence of the current invention, or mammalian cell systems (*e.g.*, COS, CHO, BHK, 293, 3T3, U937) harboring recombinant expression constructs containing a nucleotide sequence of the current invention, and promoters 30 derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter, the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for 35 the gene product being expressed. For example, when large quantities of such a protein are to be produced for the generation of pharmaceutical compositions of a protein or for

raising antibodies to the protein to be expressed, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the coding sequence of the polynucleotide to be expressed may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced, pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509), and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). If the inserted sequence encodes a relatively small polypeptide (less than 25 kD), such fusion proteins are generally soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target polypeptide can be released from the GST moiety. Alternatively, if the resulting fusion protein is insoluble and forms inclusion bodies in the host cell, the inclusion bodies may be purified and the recombinant protein solubilized using techniques well-known to one of skill in the art.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) may be used as a vector to express foreign genes (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051). In one embodiment of the current invention, SF9 insect cells are infected with a baculovirus vector expressing a peptide or protein of the current invention.

In mammalian host cells, a number of viral-based expression systems may be utilized. Specific embodiments described more fully below express tagged cDNA sequences of the current invention using a CMV promoter to transiently express recombinant protein in U937 cells or in Cos-7 cells. Alternatively, retroviral vector systems well-known in the art

may be used to insert the recombinant expression construct into host cells.

In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review, see Current

5 Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et al., 1987, Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp. 516-544; Glover, 1986, DNA  
10 Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; Bitter, 1987, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular Biology of the Yeast *Saccharomyces*, 1982, Eds. Strathern et al., Cold Spring Harbor Press, Vols. I  
15 and II.

In cases where plant expression vectors are used, the expression of the coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson et al., 1984, 20 *Nature*, 310:511-514), or the coat protein promoter of TMV (Takamatsu et al., 1987, *EMBO J.* 6:307-311) may be used.

Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al., 1984, *EMBO J.* 3:1671-1680; Broglie et al., 1984, *Science* 224:838-843); or heat shock promoters,

25 e.g., soybean hsp17.5-E or hsp17.3-B (Gurley et al., 1986, *Mol. Cell. Biol.* 6:559-565) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such  
30 techniques see, for example, Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421-463, and Grierson & Corey, 1988, Plant Molecular Biology, 2d Ed., Blackie, London, Ch. 7-9.

In cases where an adenovirus is used as an expression vector, the nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This

chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable 5 of expressing the gene product of interest in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted nucleotide sequences of interest. These signals include the ATG 10 initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a 15 coding sequence of interest is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon should be in phase with the reading frame of the desired coding sequence to ensure translation of the 20 entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see 25 Bitter *et al.*, 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and 30 processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be 35 chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper

processing of the primary transcript may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and U937 cells.

For long-term, high-yield production of recombinant

5 proteins, stable expression is preferred. For example, cell lines that stably express the sequences of interest described above may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression

10 control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.

15 The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci, which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer

20 cell lines that express the gene product of interest. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product of interest.

A number of selection systems may be used, including, but

25 not limited to, the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine

30 phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes, which can be employed in tk<sup>-</sup>, hprt<sup>-</sup> or aprt<sup>-</sup> cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the

aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, *J. Mol. Biol.* 150:1); and hygro, which confers resistance to hygromycin (Santerre *et al.*, 1984, *Gene* 30:147).

5 The novel gene products/peptide sequences encoded by the described novel GTSS are also useful as epitope tags for the antigenic or other tagging of proteins and polypeptides that have been engineered to incorporate or comprise at least a portion of an GTS peptide sequence.

10 The gene products of interest can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees, may be used to generate transgenic animals carrying one or more polynucleotide of interest of the current 15 invention.

Any technique known in the art may be used to introduce the transgene of interest into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (U.S. Pat. No.

20 4,873,191, incorporated herein by reference in its entirety); retrovirus mediated gene transfer into germ lines (Van der Putten *et al.*, 1985, *Proc. Natl. Acad. Sci., USA* 82:6148-6152); gene targeting in embryonic stem cells (Thompson *et al.*, 1989, *Cell* 56:313-321); electroporation of embryos (Lo, 1983, *Mol Cell. Biol.* 3:1803-1814); sperm-mediated gene transfer (Lavitrano *et al.*, 1989, *Cell* 57:717-723); and positive-negative selection, as described in U.S. Patent No. 25 5,464,764, herein incorporated by reference in its entirety. For a review of such techniques, see Gordon, 1989, *Transgenic 30 Animals, Intl. Rev. Cytol.* 115:171-229, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals that carry the transgene of interest in all their cells, as well as animals that carry the transgene in some, but not all 35 their cells, *i.e.*, mosaic animals. The transgene may be integrated as a single transgene or in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene

may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko *et al.* (Lasko, M. *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the transgene of interest be integrated into the chromosomal site of the endogenous copy of that same gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene of interest are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene of interest. In this way, the expression of the endogenous gene may also be eliminated by inserting non-functional sequences into the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene of interest in only that cell type, by following, for example, the teaching of Gu *et al.* (Gu *et al.*, 1994, Science 265: 103-106). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene of interest may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques that include, but are not limited to, Northern blot analysis of cell type samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR. Samples of gene-expressing tissue can also be evaluated immunocytochemically using antibodies specific for

the transgene product, as described below.

5.3. CELLS THAT CONTAIN A DISRUPTED ALLELE OF A GENE ENCODING  
A POLYNUCLEOTIDE OF THE CURRENT INVENTION

5 Another aspect of the current invention are cells that contain a gene that encodes a polynucleotide of the current invention and that has been disrupted. Those of skill in the art would know how to disrupt a gene in a cell using  
10 techniques known in the art. Also, techniques useful to disrupt a gene in a cell, and especially an ES cell, that may already be disrupted, as disclosed in U.S. Patent Nos. 6,136,566, 6,139,833 and 6,207,371, and co-pending US patent application No. 08/728,963, each of which are hereby  
15 incorporated herein by reference in their entirety, are within the scope of the current invention to disrupt a gene that encodes a polynucleotide of the current invention.

20 5.3.1 IDENTIFICATION OF CELLS THAT EXPRESS GENES ENCODING  
POLYNUCLEOTIDES OF THE CURRENT INVENTION

25 Host cells that contain coding sequence and/or express a biologically active gene product, or fragment thereof, encoded by a sequence corresponding to an GTS of the present invention may be identified by at least four general approaches: (a) DNA-DNA or DNA-RNA hybridization; (b) the presence or absence of "marker" gene functions; (c) assessing the level of transcription as measured by the expression of mRNA  
30 transcripts in the host cell; and (d) detection of the gene product as measured by immunoassay, enzymatic assay, chemical assay, or by its biological activity. Prior to screening for gene expression, the host cells can first be treated in an effort to increase the level of expression of sequences encoding polynucleotides of the current invention, especially  
35 in cell lines that produce low amounts of the mRNAs and/or peptides and proteins of the current invention.

In approach (a), the presence of the coding sequence for peptides and proteins of the current invention inserted in the expression vector can be detected by DNA-DNA or DNA-RNA

hybridization, using probes comprising nucleotide sequences that are homologous to the coding sequence for peptides and proteins of the current invention, respectively, or portions or derivatives thereof.

5        In approach (b), the recombinant expression vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, resistance to methotrexate, transformation phenotype, occlusion body  
10 formation in baculovirus, etc.). For example, if the coding sequence for the peptide or protein of the current invention is inserted within a marker gene sequence of the vector, recombinants containing the coding sequence for the peptide or protein of the current invention can be identified by the  
15 absence of marker gene function. Alternatively, a marker gene can be placed in tandem with the sequence for the peptide or protein of the current invention under the control of the same, or a different, promoter used to control the expression of the coding sequence for the peptide or protein of the  
20 current invention. Expression of the marker in response to induction or selection indicates expression of the coding sequence for the peptide or protein of the current invention.

In approach (c), transcriptional activity for the coding regions specific for peptides and proteins of the current invention can be assessed by hybridization assays. For example, RNA can be isolated and analyzed by Northern blot using a probe derived from a GTS, or any portion thereof. Alternatively, total nucleic acids of the host cell may be extracted and assayed for hybridization to such probes.

25      Additionally, RT-PCR (using GTS specific oligos/products) may be used, for example, to detect low levels of gene expression in a sample, or on RNA isolated from a spectrum of different tissues, or PCR can be used, for example, to screen a variety of cDNA libraries derived from different tissues to determine  
30 which tissues express a given GTS.

35      In approach (d), the expression of the peptides and proteins of the current invention can be assessed

immunologically, for example by Western blots, immunoassays such as radioimmuno-precipitation, enzyme-linked immunoassays and the like. This can be achieved by using an antibody, or a binding partner, specific to a peptide or protein of the 5 current invention.

#### 5.4. ANTIBODIES TO PROTEINS OF THE CURRENT INVENTION

10 Antibodies that specifically recognize one or more epitopes of a peptide or protein encoded by the GTSs of the present invention, or epitopes of conserved variants of these peptides or proteins, or any and all peptide fragments thereof, are also encompassed by the invention. Such antibodies include, but are not limited to, polyclonal 15 antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

20 The antibodies of the invention may be used, for example, in the detection of a peptide or protein of interest of the current invention in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of these 25 proteins. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes as described below in Section 5.6 for the evaluation of the effect of test compounds on expression and/or activity of the gene products of interest of the current invention. Additionally, such 30 antibodies can be used in conjunction with the gene therapy and gene delivery techniques described below to, for example, evaluate the normal and/or engineered peptide- or protein-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used in methods for 35 inhibiting the activity, either normal or abnormal, of a peptide or protein of interest of the current invention. Thus, such antibodies may, for example, be utilized as part of

409260-6626955  
treatment methods for development and/or cell differentiation disorders.

For the production of antibodies, various host animals may be immunized by injection with a peptide or protein of interest, a subunit peptide of such a protein, a truncated polypeptide, functional equivalents of the peptide or protein, mutants of the peptide or protein, or denatured forms of the above. Such host animals may include, but are not limited to, rabbits, mice, and rats, to name but a few. Various adjuvants 5 may be used to increase the immunological response, depending on the host species, including, but not limited to, Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin, pluronic polyols, polyanions, 10 peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Alternatively, the immune response 15 could be enhanced by combination and/or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, ovalbumin, cholera toxin, or fragments thereof. Polyclonal antibodies are heterogeneous populations 20 of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations 25 of antibodies to a particular antigen, may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256:495-497; and U.S. Patent No. 30 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, *Immunology Today* 4:72; Cole et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may 35 be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*.

Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, Proc. Natl.

5 Acad. Sci. USA, 81:6851-6855; Neuberger *et al.*, 1984, Nature, 312:604-608; Takeda *et al.*, 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can  
10 be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a porcine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and  
15 their respective disclosures, which are herein incorporated by reference in their entirety.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, 1988, Science 242:423-426; Huston *et al.*, 1988, Proc. Natl.

20 Acad. Sci. USA 85:5879-5883; and Ward *et al.*, 1989, Nature 341:544-546) can be adapted to produce single chain antibodies against gene products of interest. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single  
25 chain polypeptide.

Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the F(ab')<sub>2</sub> fragments, which can be produced by pepsin digestion of the antibody molecule; 30 and the Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to peptides and proteins of interest that are fully or at least partially encoded by GTSs of the current

RECEIVED  
COPYRIGHT  
REGISTRATION  
OFFICE  
U.S. PATENT AND TRADEMARK OFFICE

invention, or fragments or truncated versions thereof, can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" an epitope of the peptide or protein of interest, using techniques well-known to those skilled in the art.

5 (See, e.g., Greenspan & Bona, 1993, *FASEB J* 7(5):437-444; and Nissinoff, 1991, *J. Immunol.* 147(8):2429-2438). For example, antibodies that bind to a regulatory peptide or protein of interest of the current invention, and competitively inhibit the binding of such peptide or protein to any of its binding 10 partners in the cell, can be used to generate anti-idiotypes that "mimic" the peptide or protein of interest and, therefore, bind to and neutralize the particular binding partner of the peptide or protein of interest. Such neutralizing anti-idiotypes, or Fab fragments of such anti- 15 idotypes, can be used in therapeutic regimens to neutralize a particular binding partner of a peptide or protein of interest that plays a role in development and/or cell differentiation processes.

An additional use for the presently described knockout 20 cells and animals is the generation of high affinity antibodies against mammalian proteins. Given that the described knockout animals will have never have seen the proteins expressed by the disrupted genes, the mutated animals can recognize mammalian orthologous proteins (including highly 25 homologous human proteins) as foreign, and mount an immune response against such proteins, whereas nonmutated animals might not. Such mammalian antibodies can be humanized using readily available means, as described above, and used as therapeutic agents.

30

#### 5.5. DIAGNOSIS OF DISORDERS AFFECTING DEVELOPMENT AND CELL DIFFERENTIATION

A variety of methods can be employed for the diagnostic 35 and prognostic evaluation of disorders involving developmental and/or differentiation processes, and for the identification of subjects having a predisposition to such disorders.

Such methods may, for example, utilize reagents such as

the nucleotide sequences described above, and antibodies to peptides and proteins of the current invention, as described, in Section 5.4. Specifically, such reagents may be used, for example, for: (1) the detection of the presence of gene 5 mutations, or the detection of either over- or under-expression of the respective mRNAs relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of the respective gene product relative to the non-disorder state; and (3) the detection of perturbations or 10 abnormalities in the intra- and inter-cellular processes mediated by the respective peptides or proteins of the current invention.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising 15 at least one specific nucleotide sequence of the current invention, or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings, to diagnose patients exhibiting developmental or cell differentiation disorder abnormalities.

20 For the detection of mutations in any of the sequences described above, any nucleated cell can be used as a starting source for genomic nucleic acid. For the detection of gene expression or gene products, any cell type or tissue in which the sequence of interest is expressed, such as, for example, 25 ES cells, may be utilized. Specific examples of cells and tissues that can be analyzed using the claimed polynucleotides, or the antibodies described herein, include, but are not limited to, endothelial cells, epithelial cells, islets, neurons or neural tissue, mesothelial cells, osteocytes, lymphocytes, chondrocytes, hematopoietic cells, 30 immune cells, cells of the major glands or organs (e.g., lung, heart, stomach, pancreas, kidney, skin, etc.), exocrine and/or endocrine cells, embryonic and other stem cells, fibroblasts, and culture adapted and/or transformed versions of the above.

35 Diseases or natural processes that can also be correlated with the expression of mutant, or normal, variants of the disclosed GTSSs include, but are not limited to, aging, cancer,

autoimmune disease, lupus, scleroderma, Crohn's disease, multiple sclerosis, inflammatory bowel disease, immune disorders, schizophrenia, psychosis, alopecia, glandular disorders, inflammatory disorders, ataxia telangiectasia, 5 diabetes, skin disorders such as acne, eczema, and the like, osteo and rheumatoid arthritis, high blood pressure, atherosclerosis, cardiovascular disease, pulmonary disease, degenerative diseases of the neural or skeletal systems, Alzheimer's disease, Parkinson's disease, osteoporosis, 10 asthma, developmental disorders or abnormalities, genetic birth defects, infertility, epithelial ulcerations, and viral, parasitic, fungal, yeast, or bacterial infections.

Primary, secondary, or culture adapted variants of cancer cells/tissues can also be analyzed using the claimed

15 polynucleotides, and/or the antibodies described herein. Examples of such cancers include, but are not limited to, cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, 20 mesothelioma; gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, 25 tubular adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (30 seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); liver:

hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, 5 Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; nervous system: skull (osteoma, 10 hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiforme, oligodendrolioma, schwannoma, retinoblastoma, congenital tumors), spinal cord 15 (neurofibroma, meningioma, glioma, sarcoma); gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid tumors, celioblastoma, clear cell carcinoma, 20 unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma 25 (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma 30 (malignant lymphoma); skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles, dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; breast: carcinoma and sarcoma, and adrenal glands: neuroblastoma.

35 Nucleic acid-based detection techniques and peptide detection techniques that can be used to conduct the above analyses are described below.

5.5.1. DETECTION OF THE SEQUENCES OF THE CURRENT INVENTION AND  
THEIR RESPECTIVE TRANSCRIPTS

5 Mutations within the polynucleotide sequences of the  
current invention can be detected by utilizing a number of  
techniques. Nucleic acid from any nucleated cell can be used  
as the starting point for such assay techniques, and may be  
isolated according to standard nucleic acid preparation  
procedures, which are well-known to those of skill in the art.

10 DNA may be used in hybridization or amplification assays  
of biological samples to detect abnormalities involving gene  
structure, including point mutations, insertions, deletions  
and chromosomal rearrangements. Such assays may include, but  
are not limited to, Southern analyses, single stranded  
15 conformational polymorphism analyses (SSCP), and PCR analyses.

Such diagnostic methods for the detection of sequence-  
specific mutations can involve for example, contacting and  
incubating nucleic acids, including recombinant DNA molecules,  
cloned genes or degenerate variants thereof, obtained from a  
20 sample, e.g., derived from a patient sample or other  
appropriate cellular source, with one or more labeled nucleic  
acid reagents, including recombinant DNA molecules, cloned  
genes or degenerate variants thereof, as described above,  
under conditions favorable for the specific annealing of these  
25 reagents to their complementary sequences within the sequence  
of interest of the current invention. Preferably, the lengths  
of these nucleic acid reagents are at least 15 to 30  
nucleotides. After incubation, all non-annealed nucleic acids  
are removed from the nucleic acid molecule hybrid. The  
30 presence of nucleic acids that have hybridized, if any such  
molecules exist, is then detected. Using such a detection  
scheme, the nucleic acids from the cell type or tissue of  
interest can be immobilized, for example, to a solid support  
such as a membrane, or a plastic surface such as that on a  
35 microtiter plate or polystyrene beads. In this case, after  
incubation, non-annealed, labeled nucleic acid reagents of the  
type described above are easily removed. Detection of the  
remaining, annealed, labeled nucleic acid reagents is

accomplished using standard techniques well-known to those in the art. The sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal sequence in order to determine whether a genetic mutation is present.

Alternative diagnostic methods for the detection of specific nucleic acid molecules, in patient samples or other appropriate cell sources, may involve their amplification, e.g., by PCR (the experimental embodiment set forth in U.S. Patent No. 4,683,202), followed by the detection of the amplified molecules using techniques well-known to those of skill in the art. The resulting amplified sequences can be compared to those that would be expected if the nucleic acid being amplified contained only normal copies of the respective sequence in order to determine whether a genetic mutation exists.

Additionally, well-known genotyping techniques can be performed to identify individuals carrying mutations in any of the polynucleotide sequences of the current invention. Such techniques include, for example, the use of restriction fragment length polymorphisms (RFLPs), which involves sequence variations in one of the recognition sites for the specific restriction enzyme used.

Furthermore, the polynucleotide sequences of the current invention may be mapped to chromosomes and specific regions of chromosomes using well-known genetic and/or chromosomal mapping techniques. These techniques include *in situ* hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent *in situ* hybridization of chromosome spreads has been described, for example, in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York. Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can

be found, for example, in "Genetic Maps: Locus Maps of Complex Genomes, Book 5: Human Maps", O'Brien, editor, Cold Spring Harbor Laboratory Press (1990). Comparisons of physical chromosomal map data may be of particular interest in  
5 detecting genetic diseases in carrier states.

The level of expression of nucleotide sequences can also be assayed by detecting and measuring the transcription of such sequences. For example, RNA from a cell type or tissue known, or suspected, to express any of the sequences of the  
10 current invention can be isolated and tested utilizing hybridization or PCR techniques (e.g., northern or RT PCR), such as those described above. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the respective sequence, including activation or  
15 inactivation of gene expression. *In situ* hybridization using suitably radioactively or enzymatically labeled forms of the described polynucleotide sequences can also be used to assess expression patterns *in vivo*.

Additionally, an oligonucleotide or polynucleotide sequence first disclosed in at least a portion of one or more of the GTS sequences of SEQ ID NOS: 1-1,000 can be used as a hybridization probe in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or  
25 polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (i.e., gene chips, microtiter plates, etc.) of oligonucleotides and polynucleotides, or corresponding oligopeptides and polypeptides, wherein at least one of the biopolymers present on the spatially addressable  
30 array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS: 1-1,000, or an amino acid sequence encoded thereby. Methods for attaching biopolymers to, or synthesizing  
35 biopolymers on, solid support matrices, and conducting binding studies thereon are disclosed in, *inter alia*, U.S. Patent Nos. 5,700,637, 5,556,752, 5,744,305, 4,631,211, 5,445,934, 5,252,743, 4,713,326, 5,424,186, and 4,689,405, the

disclosures of which are herein incorporated by reference in their entirety.

Addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-1,000 can be used to identify and characterize the temporal and tissue specific expression of a gene. These addressable arrays incorporate oligonucleotide sequences of sufficient length to confer the required specificity, yet be within the limitations of the production technology. The length of these probes is within a range of between about 8 to 10 about 2000 nucleotides. Preferably the probes consist of 60 nucleotides, and more preferably 25 nucleotides, from the sequences first disclosed in SEQ ID NOS:1-1,000.

For example, a series of the described GTS oligonucleotide sequences, or the complements thereof, can be used in chip format to represent all or a portion of the described GTS sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length can partially overlap each other, and/or the GTS sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described GTS polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 8 nucleotides in length that are each first disclosed in the appended Sequence Listing. Such oligonucleotide sequences can begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence, or in an antisense (3'-to-5') orientation.

Microarray-based analysis allows the discovery of broad patterns of genetic activity, providing new understanding of gene functions and generating novel and unexpected insight into transcriptional processes and biological mechanisms. The use of addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-1,000 provides detailed information about transcriptional changes involved in a specific pathway, potentially leading to the identification of novel components or gene functions that manifest themselves as novel

phenotypes.

Probes consisting of sequences first disclosed in SEQ ID NOS:1-1,000, or portions thereof, can also be used in the identification, selection and validation of novel molecular targets for drug discovery. The use of these unique sequences permits the direct confirmation of drug targets and recognition of drug dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. These unique sequences therefore also have utility in defining and monitoring both drug action and toxicity.

As an example of utility, the sequences first disclosed in SEQ ID NOS:1-1,000, or fragments thereof, can be utilized in microarrays or other assay formats, to screen collections of genetic material from patients who have, or are at risk of developing, a particular medical condition. These investigations can also be carried out using the sequences first disclosed in SEQ ID NOS:1-1,000 *in silico*, and by comparing previously collected genetic databases and the disclosed sequences using computer software known to those in the art.

Thus, the sequences first disclosed in SEQ ID NOS:1-1,000, or portions thereof, can be used to identify mutations associated with a particular disease, and also in diagnostic or prognostic assays.

Although the presently described GTSs have been specifically described using nucleotide sequence, it should be appreciated that each of the GTSs can uniquely be described using any of a wide variety of additional structural attributes, or combinations thereof. For example, a given GTS can be described by the net composition of the nucleotides present within a given region of the GTS in conjunction with the presence of one or more specific oligonucleotide sequence(s) first disclosed in the GTS. Alternatively, a restriction map specifying the relative positions of restriction endonuclease digestion sites, or various palindromic or other specific oligonucleotide sequences can be

used to structurally describe a given GTS. Such restriction maps, which are typically generated by widely available computer programs (e.g., the University of Wisconsin GCG sequence analysis package, SEQUENCER 3.0, Gene Codes Corp., 5 Ann Arbor, MI, etc.), can optionally be used in conjunction with one or more discrete nucleotide sequence(s) present in the GTS that can be described by the relative position of the sequence relative to one or more additional sequence(s) or one or more restriction sites present in the GTS.

10

#### 5.5.2. DETECTION OF THE GENE PRODUCTS OF THE CURRENT INVENTION

Antibodies directed against wild type or mutant gene products of the current invention, or conserved variants or peptide fragments thereof, which are discussed above in 15 Section 5.4 may also be used as diagnostics and prognostics for disorders affecting development and/or cellular differentiation, as described herein. Such diagnostic methods, may be used to detect abnormalities in the level of 20 gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of the respective gene product, and may be performed *in vivo* or *in vitro*, such as, for example, on biopsy tissue.

The tissue or cell type to be analyzed will generally 25 include those that are known, or suspected, to contain cells that express the respective sequence. The protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor 30 Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety. The isolated cells can be derived, for example, from cell culture or from a patient. The analysis of cells taken from culture 35 may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the respective polynucleotide sequence.

For example, antibodies, or fragments of antibodies, such

109260-6025960

as those described above in Section 5.4, are also useful in the present invention to quantitatively or qualitatively detect the presence of gene products of the current invention or conserved variants or peptide fragments thereof. This can 5 be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below, this Section) coupled with light microscopic, flow cytometric, or fluorimetric detection.

10 The antibodies (or fragments thereof) or fusion or conjugated proteins useful in the present invention may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immuno assays, for *in situ* detection of gene products of the current invention or conserved variants or peptide fragments thereof, 15 or for catalytic subunit binding (in the case of labeled catalytic subunit fusion proteins).

19 *In situ* detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody, fragment thereof, or fusion protein of the present invention. The antibody (or fragment) or fusion protein is preferably applied by overlaying the labeled antibody (or fragment) or fusion protein onto a biological sample. Through the use of such a procedure, it is possible 20 to determine not only the presence of the gene product of the current invention, or conserved variants or peptide fragments, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily 25 perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

30 Immunoassays and non-immunoassays for gene products of the current invention or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly 35 harvested cells, or lysates of cells that have been incubated in cell culture, in the presence of a detectably labeled antibody or fragment capable of identifying the respective

gene products of interest or conserved variants or peptide fragments thereof, and detecting the bound antibody or fragment by any of a number of techniques well-known in the art.

5        The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support that is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by  
10      treatment with the detectably labeled antibody or fragment specific to the peptide or protein of interest of the current invention, or with a fusion protein. The solid phase support may then be washed with the buffer a second time to remove unbound antibody, fragment or fusion protein. The amount of  
15      bound label remaining on the solid support may then be detected by conventional means.

"Solid phase support or carrier" is intended to encompass any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface  
25      may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

35      The binding activity of a given lot of antibody, fragment thereof, or fusion protein may be determined according to well-known methods. Those skilled in the art will be able to

determine operative and optimal assay conditions for each determination by employing routine experimentation.

With respect to antibodies, one of the ways in which the

antibody can be detectably labeled is by linking the same to an enzyme for use in an enzyme immunoassay (EIA) (Voller, "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD; Voller et al., 1978, J. Clin. Pathol. 31:507-520; Butler, 1981, Meth. Enzymol. 73:482-523; Maggio (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL; and Ishikawa et al., (eds.), 1981, Enzyme Immunoassay, Kagaku Shoin, Tokyo). The enzyme that is bound to the antibody or fragment will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes that can be used to detectably label the antibody or fragment include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods that employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect the peptide or protein of interest through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein in its

entirety). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

It is also possible to label the antibody or fragment with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can be detected due to fluorescence. Exemplary fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin and fluorescamine.

The antibody or fragment can also be detectably labeled using fluorescence emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the antibody or fragment using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody or fragment also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibodies of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems, in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Exemplary bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

An additional use of a peptide or polypeptide encoded by an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS: 1-1,000 involves incorporating the sequence into a phage display, or other peptide library/binding, system that can be used to

105250 6625960

screen for proteins, or other ligands, that are capable of binding to an amino acid sequence encoded by an oligonucleotide or polynucleotide sequence first disclosed in at least one of the GTS sequences of SEQ ID NOS: 1-1,000 (see

5 U.S. Patents Nos. 5,270,170, and 5,432,018, herein incorporated by reference in their entirety). Moreover, peptide arrays comprising a novel amino acid sequence corresponding to a portion of at least one of the polynucleotide sequences first disclosed in SEQ ID NOS: 1-  
10 1,000 can be generated and screened essentially as described in U.S. Patents Nos. 5,143,854, 5,405,783, and 5,252,743, the complete disclosures of which are herein incorporated by reference.

15 Additionally, the presently described GTSSs, or primers derived therefrom, can be used to screen spatially addressable arrays, or pools therefrom, of clones present in a full-length human cDNA library. The 96 well microtiter plate format is especially well suited to the screening, by PCR for example, of pooled subfractions of cDNA clones.

20

5.6. SCREENING ASSAYS FOR COMPOUNDS THAT MODULATE THE EXPRESSION OR ACTIVITY OF PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

25 The following assays are designed to identify compounds that interact with (e.g., bind to) peptides and proteins at least partially encoded by one of SEQ ID NOS: 1-1,000 (i.e., peptides or proteins of the current invention), compounds that interact with (e.g., bind to) intracellular proteins that  
30 interact with peptides and proteins of the current invention, compounds that interfere with the interaction of peptides and proteins of the current invention with each other and with other intracellular proteins involved in developmental and cell differentiation processes, and to compounds that modulate  
35 the activity of the polynucleotide sequences of the current invention (i.e., modulate the level of expression of the sequences of the current invention) or modulate the level of gene products of the current invention. Assays may

additionally be utilized that identify compounds that bind to gene regulatory sequences (e.g., promoter sequences), and that may modulate the expression of sequences of the current invention. See e.g., Platt, K.A., 1994, J. Biol. Chem.

5 269:28558-28562, which is incorporated herein by reference in its entirety.

Compounds that can be screened in accordance with the invention include, but are not limited to: proteins, polypeptides, peptides, antibodies and fragments thereof, 10 prostaglandins, lipids and other organic compounds (e.g., terpines, peptidomimetics) that bind to the peptide or protein of interest of the current invention and either mimic the activity triggered by the natural ligand (i.e., agonists) or inhibit the activity triggered by the natural ligand (i.e., antagonists); as well as proteins, polypeptides, peptides, 15 antibodies or fragments thereof, and other organic compounds that mimic the peptide or protein of interest of the current invention (or a portion thereof) and bind to and "neutralize" natural ligand.

20 Such compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries (see, e.g., Lam, K.S. et al., 1991, Nature 354:82-84; Houghten, R. et al., 1991, Nature 354:84-86), and combinatorial chemistry-derived

25 molecular library peptides made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to members of random or partially degenerate, directed phosphopeptide libraries (see, e.g., Songyang, Z. et al., 1993, Cell 72:767-778)); antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')<sub>2</sub> and Fab expression library fragments, and epitope-binding fragments thereof); and small organic or inorganic molecules.

30 Other compounds that can be screened in accordance with the invention include, but are not limited to: small organic molecules that are able to gain entry into an appropriate cell (e.g., ES cells) and affect the expression of a sequence of

109260 6622960

the current invention or some other gene or sequence involved in development and cell differentiation (e.g., by interacting with the regulatory region or transcription factors involved in gene expression); or compounds that affect the activity of 5 the peptide or protein of interest of the current invention, e.g., by inhibiting or enhancing the binding of such peptide or protein to another cellular peptide or protein, or other factor, necessary for catalysis, signal transduction, or the like, that is involved in developmental and/or cell 10 differentiation processes.

Computer modeling and searching technologies permit the identification of compounds, or the improvement of already identified compounds, which can modulate the expression or activity of peptides or proteins of interest of the current 15 invention. Having identified such a compound or composition, the active sites or regions can be identified. Such active sites might typically be the binding partner sites, such as, for example, the interaction domains of the peptides and proteins of the current invention with their respective 20 binding partners. The active site can be identified using methods known in the art including, for example, from study of the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In 25 the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three-dimensional geometric structure of the active site is determined. This can be done by known methods, 30 including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other experimental method of structure determination can be used to obtain partial or 35 complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure

determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy.

- 5 Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most
- 10 types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the
- 15 complete and more accurate structures computed by these modeling methods.

Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination thereof, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. Those compounds found from this search are potential modulating compounds of the peptides and proteins of interest of the current invention.

- 20
- 25
- 30
- 35

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly

evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active sites of peptides and proteins of interest of the current invention, and related factors involved in development, cellular differentiation, and/or other cellular processes will be apparent to those of skill in the art.

Examples of molecular modeling systems are the CHARM and QUANTA programs (Polygon Corporation, Waltham, MA). CHARM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen *et al.*, 1988, *Acta Pharmaceutical Fennica* 97:159-166; Ripka, *New Scientist* 54-57 (June 16, 1988); McKinlay and Rossmann, 1989, *Annu. Rev. Pharmacol. Toxicol.* 29:111-122; Perry and Davies, OSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); and Lewis and Dean, 1989, *Proc. R. Soc. Lond.* 236:125-140 and 141-162; and, with respect to a model receptor for nucleic acid components, Askew *et al.*, 1989, *J. Am. Chem. Soc.* 111:1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to the design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to the design and generation of compounds that could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active

materials, including proteins, for compounds that are inhibitors or activators.

Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the gene products of interest of the current invention, and for ameliorating disorders affecting development and/or cell differentiation. Assays for testing the effectiveness of compounds, identified by, for example, techniques such as those described below.

10

#### 5.6.1. *IN VITRO* SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

*In vitro* systems may be designed to identify compounds capable of interacting with (e.g., binding to) peptides and proteins of interest of the current invention, fragments thereof, and variants thereof. The identified compounds can be useful, for example, in modulating the activity of wild type and/or mutant gene products of the current invention, in screens for identifying compounds that disrupt normal interactions of the peptides and proteins of the current invention with other factors, like, for example, other peptides and proteins, or may in themselves disrupt such interactions.

25 The principle of the assays used to identify compounds that bind to the peptides and proteins of the current invention involves preparing a reaction mixture of the peptides and proteins of interest that are disclosed by the current invention and a test compound under conditions and for 30 a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed from and/or detected in the reaction mixture. The peptides and proteins of the current invention that are used can vary depending upon the goal of the screening assay. For example, where agonists 35 of the natural ligand are sought, the full length peptide or protein of interest, or a fusion protein containing the protein or portion thereof of interest fused to a protein or polypeptide that affords advantages in the assay system (e.g.,

labeling, isolation of the resulting complex, etc.) can be utilized.

The screening assays can be conducted in a variety of ways. For example, one method of conducting such an assay 5 involves anchoring the peptide or protein of interest of the current invention, or a fusion protein thereof, or the test substance onto a solid phase and detecting peptide or protein of interest/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a 10 method, the peptide or protein of interest may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly. In another embodiment of the method, a peptide or protein of interest of the current invention anchored on the solid phase 15 is complexed with a natural ligand of such peptide or protein. Then, a test compound could be assayed for its ability to disrupt the association of the complex.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be 20 immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a 25 monoclonal antibody, specific for the peptide or protein to be immobilized may be used to anchor the peptide or protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized 30 component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where 35 the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized

component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or 5 indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected, e.g., using an immobilized antibody specific for one component of complexes formed, like, 10 for example, the peptide or protein of interest of the current invention or the test compound, to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

15

#### 5.6.2. ASSAYS FOR INTRACELLULAR PROTEINS THAT INTERACT WITH THE PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

Any method suitable for detecting protein-protein 20 interactions can be employed for identifying intracellular peptides and proteins that interact with peptides and proteins of the current invention. Exemplary methods that may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of 25 cell lysates, or proteins obtained from cell lysates, and the peptides and proteins of the current invention, to identify proteins in the lysate that interact with the peptides and proteins of the current invention. For these assays, the peptides and proteins of the current invention may be used in 30 full length, truncated or modified forms, as fusion-proteins, or as a complex of two or more of the peptides and proteins of the current invention. Once isolated, such an intracellular protein can be identified and can, in turn, be used, in conjunction with standard techniques, to identify proteins 35 with which it interacts. For example, at least a portion of the amino acid sequence of an intracellular protein that interacts with a peptide or protein of the current invention can be ascertained using techniques well-known to those of

1026162660

skill in the art, such as via the Edman degradation technique (see, e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles", W.H. Freeman & Co., N.Y., pp.34-49).

5 The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for sequences encoding such intracellular proteins. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are

10 well-known (see, e.g., Ausubel, *supra*, and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds. Academic Press, Inc., New York).

15 Additionally, methods may be employed that result in the simultaneous identification of genes that encode the intracellular proteins interacting with peptides and proteins of the current invention. These methods include, for example, probing expression libraries, in a manner similar to the well-known technique of antibody probing of  $\lambda$ gt11 libraries, using a labeled form of a peptide or protein of the current

20 invention, or a fusion protein, e.g., a peptide or protein at least partially encoded by an GTS of the current invention fused to a marker (e.g., an enzyme, fluor, luminescent protein, or dye), or an Ig-Fc domain.

One method that detects protein interactions *in vivo*, the 25 two-hybrid system, is described in detail for illustration only and not by way of limitation. One version of this system utilizes yeast cells (Chien et al., 1991, Proc. Natl. Acad. Sci. USA, 88:9578-9582), while another uses mammalian cells (Luo et al., 1997, Biotechniques 22:350-352). Both yeast and 30 mammalian two-hybrid systems are commercially available from Clontech (Palo Alto, CA).

Briefly, utilizing such a system, plasmids are 35 constructed that encode two hybrid proteins: one plasmid consists of nucleotides encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence of the current invention encoding a peptide or protein of the current invention, a modified or truncated form or a fusion

protein, and another plasmid consists of nucleotides encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein that has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast *Saccharomyces cerevisiae* or a mammalian cell (such as a Saos-2, CHO, CV1, Jurkat or HeLa cell) that contains a reporter gene (e.g., HBS, lacZ or CAT) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene; the DNA-binding domain hybrid cannot because it does not provide activation function, and the activation domain hybrid cannot because it cannot localize to the activator's binding site. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, a peptide or protein of the current invention may be used as the bait gene product. Total genomic or cDNA sequences are fused or operably linked to DNA encoding an activation domain. This library and a plasmid encoding a hybrid of a bait gene product of the current invention fused to the DNA-binding domain are co-transformed into a reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, and not by way of limitation, a bait sequence of the current invention can be cloned into a vector such that it is translationally fused to DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

A cDNA library of the cell line from which proteins that interact with bait gene product of the current invention are

to be detected can be made using methods routinely practiced in the art. According to the particular systems described herein, for example, the cDNA fragments can be inserted into a vector such that they are translationally fused or linked to the transcriptional activation domain of GAL4. This library can be co-transfected along with the bait sequence-GAL4 fusion plasmid into a yeast strain that cannot grow without added histidine, which contains a HIS3 gene driven by a promoter that contains GAL4 activation sequence. A cDNA encoded protein fused to GAL4 transcriptional activation domain that interacts with bait gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies that express HIS3 can be detected by their growth on petri dishes containing semi-solid agar based media lacking histidine. The cDNA can then be purified from these strains, and used to produce and isolate the bait sequence-interacting protein using techniques routinely practiced in the art.

5.6.3. ASSAYS FOR COMPOUNDS THAT INTERFERE WITH INTERACTIONS  
20 OF THE PEPTIDES AND PROTEINS OF THE CURRENT INVENTION WITH  
INTRACELLULAR MACROMOLECULES

Macromolecules that interact with the peptides and proteins of the current invention are referred to, for purposes of this discussion, as "binding partners". These binding partners are likely to be involved in catalytic reactions or signal transduction pathways, and therefore, in the role of the peptides and proteins of the current invention in development and/or cell differentiation. It is also desirable to identify compounds that interfere with or disrupt the interaction of such binding partners with the peptides and proteins of the current invention. Such compounds may be useful in regulating the activity of the peptides and proteins of the current invention, and thus control development and/or cell differentiation disorders associated with the activity of these peptides and proteins.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the

peptides and proteins of the current invention and its binding partner or partners involves preparing a reaction mixture containing the peptides or proteins of the current invention of interest, modified or truncated version thereof, or fusion

5 proteins thereof as described above, and a binding partner under conditions and for a time sufficient to allow the components to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test

10 compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of the peptide or protein of the current invention and a binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The

15 formation of complexes between the peptide or protein of the current invention and the binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the

20 peptide or protein at least partially encoded by an GTS of the present invention and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal peptide or protein of the current invention may also be compared to complex

25 formation within reaction mixtures containing the test compound and a mutant peptide or protein of the current invention. This comparison may be important in those cases where it is desirable to identify compounds that disrupt interactions of mutant but not normal forms of a peptide or

30 protein of the current invention.

Assays for compounds that interfere with the interaction of a peptide or protein of the current invention and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the

35 peptide or protein of the current invention or a binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous

assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with 5 the interaction by competition can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the peptide or protein of the current invention and interactive binding partner. Alternatively, 10 test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

15 In a heterogeneous assay system, either the peptide or protein of the current invention or the interactive binding partner is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly. In practice, microtiter plates are conveniently utilized. The 20 anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the peptide or protein of the current invention or binding partner and drying. Alternatively, an immobilized 25 antibody or fragment thereof specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the partner of the 30 immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non- 35 immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled,

an indirect label can be used to detect complexes anchored on the surface, e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or disrupt preformed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound. The reaction products are separated from unreacted components, and complexes detected, e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex formation or that disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a preformed complex of the peptide or protein of the current invention and the interactive binding partner is prepared in which either the peptide or protein of the current invention or its binding partner is labeled, but the signal generated by the label is quenched due to formation of the complex (see, e.g., U.S. Patent No. 4,109,496, which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt the interaction of the peptide or protein of the current invention and the intracellular binding partner can be identified.

In a particular embodiment, a peptide or protein of the current invention can be prepared for immobilization. For example, a peptide or protein of the current invention or a fragment thereof can be fused to a glutathione-S-transferase (GST) sequence using a fusion vector, such as pGEX-5X-1, in such a manner that the binding activities are maintained in

the resulting fusion protein. The interactive binding partner can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art and described above.

5 This antibody can be labeled with a radioactive isotope, <sup>125</sup>I for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., such fusion proteins of GST and the peptides or proteins of the present invention can be anchored to glutathione-agarose beads. An interactive binding partner can then be added in the presence or absence of the test 10 compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and a labeled monoclonal antibody that binds to the binding partner can be added to the system and allowed to bind to the complexed binding partner. The 15 interaction between the peptide or protein of the current invention and the interactive binding partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result 20 in a decrease in measured radioactivity.

Alternatively, a GST-peptide or protein of the current invention fusion protein and an interactive binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added 25 either during or after the species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the peptide or protein of the current invention/binding partner interaction can be detected by 30 adding a labeled antibody that binds to the binding partner and measuring the radioactivity associated with the beads.

In another embodiment of the invention, in which the binding partner is a protein, these same techniques can be employed using peptide fragments that correspond to one or 35 more of the binding domains of a peptide or protein of the current invention and/or the interactive or binding partner in place of one or both of the full length proteins. Any number

of methods routinely practiced in the art can be used to identify and isolate the binding domains or regions. These methods include, but are not limited to, mutagenesis of a sequence encoding one of the proteins and screening for 5 disruption of binding in a co-immunoprecipitation assay. Compensating mutation(s) in the sequence encoding the second species in the complex can then be selected. Sequence analysis of the sequences encoding the respective proteins will reveal the mutations that correspond to the regions of 10 the proteins involved in interactive binding. Alternatively, one protein can be anchored to a solid surface, using methods described above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, 15 labeled peptide comprising a binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the sequence encoding the intracellular binding partner is obtained, short polynucleotide segments can be engineered to express peptide 20 fragments of the protein, which can then be tested for binding activity and purified or synthesized.

For example, and not by way of limitation, a peptide or protein of the current invention can be anchored to a solid material, as described above, by making a GST-peptide or 25 protein of the current invention fusion protein and allowing it to bind to glutathione agarose beads. The interactive binding partner can be labeled with a radioactive isotope, such as  $^{35}\text{S}$ , and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored 30 GST-peptide or protein of the current invention fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing an intracellular binding partner binding domain, can be eluted, purified, and analyzed for amino acid sequence by well-known methods. Peptides so 35 identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

5.6.4. ASSAYS FOR IDENTIFICATION OF COMPOUNDS THAT AMELIORATE  
DISORDERS AFFECTING DEVELOPMENT AND CELL DIFFERENTIATION

5 Compounds, including but not limited to binding compounds identified via assay techniques such as those described above, can be tested for the ability to ameliorate development and/or cell differentiation disorder symptoms. The assays described above can identify compounds that affect the activity of  
10 peptides and proteins of the current invention (e.g., compounds that bind to the peptides and proteins of the current invention, inhibit binding of their natural ligands, and compounds that bind to a natural ligand of the peptides and proteins of the current invention and neutralize the  
15 ligand activity), or compounds that affect the activity of the nucleotide sequences encoding peptides and proteins of the current invention (by affecting the expression of those nucleotide sequences, including molecules, e.g., proteins or small organic molecules, that affect or interfere with  
20 splicing events so that expression of the nucleotide sequences of interest can be modulated). However, it should be noted that the assays described herein can also identify compounds that modulate signal transduction or catalytic events that the peptides and proteins of the current invention are involved  
25 in. The identification and use of such compounds that affect a step in, for example, signal transduction pathways or catalytic events in which any of the peptides and proteins of the current invention are involved in, may modulate the effect of the peptides and proteins of the current invention on  
30 developmental and/or cell differentiation disorders. Such identification and use of such compounds are within the scope of the invention. Such compounds can be used as part of a therapeutic method for the treatment of developmental and/or cell differentiation disorders.

35 The invention encompasses cell-based and animal model-based assays for the identification of compounds exhibiting an ability to ameliorate developmental and cell differentiation disorder symptoms. Such cell-based assay systems can also be

used as the standard to assay for purity and potency of the natural ligand(s), catalytic subunit(s), including recombinantly or synthetically produced catalytic subunit(s), and catalytic subunit mutants.

5 Cell-based systems used to identify compounds that may act to ameliorate developmental or cell differentiation disorder symptoms can include, for example, recombinant or non-recombinant cells, such as cell lines, which express a sequence encoding the peptide or protein of interest of the  
10 current invention. For example ES cells, or cell lines derived from ES cells, can be used. In addition, expression host cells (e.g., COS cells, CHO cells, fibroblasts, Sf9 cells) genetically engineered to express a functional peptide or protein of the current invention, in addition to factors  
15 necessary for the peptide or protein of the current invention to fulfil its physiological role of, for example, signal transduction or catalysis, can be used in these assays.

In utilizing such cell systems, cells may be exposed to a compound suspected of exhibiting an ability to ameliorate  
20 developmental or cell differentiation disorder symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of such disorder symptoms in the exposed cells. After exposure, the cells can be assayed to measure alterations in the expression of the sequence encoding the  
25 peptide or protein of interest of the current invention, e.g., by assaying cell lysates for the appropriate mRNA transcripts (e.g., by Northern analysis) or for expression of the peptide or protein of interest of the current invention in the cell. Compounds that regulate or modulate expression of the gene  
30 encoding the peptide or protein of interest of the current invention are valuable candidates as therapeutics.

Alternatively, the cells can be examined to determine whether one or more developmental or cell differentiation disorder-like cellular phenotypes has been altered to resemble  
35 a more normal or more wild type phenotype, or a phenotype more likely to produce a lower incidence or severity of disorder symptoms. Still further, the expression and/or activity of

100-6626560

components of pathways, or functionally or physiologically connected peptides or proteins of which the peptide or protein of interest of the current invention is a part, can be assayed.

5 For example, after exposure of the cells to a test compound, cell lysates can be assayed for the presence of increased levels of the assay compound as compared to lysates derived from unexposed control cells. The ability of a test compound to inhibit production of the assay compound in such 10 systems indicates that the test compound inhibits signal transduction initiated by the peptide or protein of interest of the current invention. Finally, a change in cellular morphology of intact cells may be assayed using techniques well-known to those of skill in the art.

15 In addition, animal-based development or cell differentiation disorder systems, which may include, for example, mice, may be used to identify compounds capable of ameliorating development or cell differentiation disorder or disorder-like symptoms. Such animal models may be used as 20 test systems for the identification of drugs, pharmaceuticals, therapies and interventions that may be effective in treating such disorders. For example, animal models may be exposed to a compound suspected of exhibiting an ability to ameliorate development or cell differentiation disorder symptoms, at a 25 sufficient concentration and for a time sufficient to elicit such an amelioration of development and/or cell differentiation disorder symptoms in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with 30 development and/or cell differentiation disorders. With regard to intervention, any treatments that reverse any aspect of development or cell differentiation disorder or disorder-like symptoms should be considered as candidates for human development and/or cell differentiation disorder therapeutic 35 intervention. Dosages of test agents may be determined by deriving dose-response curves, as discussed herein.

5 .7. THE TREATMENT OF DISORDERS ASSOCIATED WITH STIMULATION OF  
5 PEPTIDES AND PROTEINS OF THE CURRENT INVENTION

The invention also encompasses methods and compositions  
5 for modifying development and/or cell differentiation and  
treating development and/or cell differentiation disorders.  
For example, one may increase or decrease the level of  
expression of one or more sequences of the current invention,  
and/or upregulate or downregulate activity of one or more of  
10 the peptides or proteins of the current invention. Thereby,  
the response of cells, like, for example, ES cells, to factors  
that activate or repress the physiological responses that  
enhance the pathological processes leading to developmental  
and/or cell differentiation disorders may be altered (reduced  
15 or increased) and the symptoms ameliorated. Conversely, the  
response of cells, like, for example, ES cells, to  
physiological stimuli involving any of the peptides or  
proteins of the current invention and necessary for proper (or  
improper) developmental and/or cell differentiation processes  
20 may be augmented (or decreased) by increasing (or decreasing)  
the activity of one or several of the peptides or proteins of  
the current invention. Different approaches are discussed  
below.

25 5.7.1. INHIBITION OF PEPTIDES AND PROTEINS OF THE CURRENT  
INVENTION TO REDUCE DEVELOPMENT AND CELL DIFFERENTIATION  
DISORDERS

Any method that neutralizes the catalytic or signal  
30 transduction activity of peptides and proteins at least  
partially encoded by the GTSSs of the current invention, or  
that inhibits expression of the genes encoding peptides and  
proteins (either transcription or translation), can be used to  
reduce symptoms associated with developmental and/or cell  
35 differentiation disorders.

In one embodiment, immunotherapy can be designed to  
reduce the level of endogenous expression of the peptides and  
proteins of the current invention, e.g., using antisense or  
ribozyme approaches to inhibit or prevent translation of mRNA

transcripts; triple helix approaches to inhibit transcription of the sequences; or targeted homologous recombination to inactivate or "knock out" the sequences or their endogenous promoters.

5 Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are complementary to mRNA specific for peptides and proteins of interest of the current invention. The antisense oligonucleotides will bind to the complementary mRNA transcripts and prevent translation.

10 Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex.

15 In the case of double-stranded antisense nucleic acids, a single strand of the normally duplex DNA can thus be tested, or triplex formation can be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an

20 RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

25 Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation

30 of mRNAs as well (see generally, Wagner, R., 1994, *Nature* 372:333-335). Thus, oligonucleotides complementary to either the 5'- or 3'- non-translated, non-coding regions of the mRNAs specific for the peptides and proteins of the current invention could be used in an antisense approach to inhibit

35 translation of those endogenous mRNAs. Oligonucleotides complementary to the 5' untranslated region of the mRNA may, in certain preferred embodiments, include the complement of

the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions can also be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of an mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides in length.

10        Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene 15 inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense 20 oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide, and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more 25 than is necessary to prevent specific hybridization to the target sequence.

30        The oligonucleotides can be DNA, RNA, chimeric mixtures, derivatives or modified versions thereof, and can be single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), agents facilitating transport across 35 the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; and PCT Publication No.

WO88/09810, published December 15, 1988), hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, BioTechniques 6:958-976), or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the 5 oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety that is selected from the group 10 including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- 15 galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 20 beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiacytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid 25 methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, 30 but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose. In another embodiment, the antisense oligonucleotide comprises at least one modification of the phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a 35 phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

1 In yet another embodiment, the antisense oligonucleotide  
2 is an alpha-anomeric oligonucleotide. An alpha-anomeric  
3 oligonucleotide forms specific double-stranded hybrids with  
4 complementary RNA in which, contrary to the usual alpha-units,  
5 the strands run parallel to each other (Gautier et al., 1987,  
Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-0-  
methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res.  
15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al.,  
1987, FEBS Lett. 215:327-330).

10 Oligonucleotides of the invention may be synthesized by  
standard methods known in the art, e.g., by use of an  
automated DNA synthesizer (such as are commercially available  
from Biosearch, Applied Biosystems, etc.). As examples,  
15 phosphorothioate oligonucleotides may be synthesized by the  
method of Stein et al., 1988, Nucl. Acids Res. 16:3209, and  
methylphosphonate oligonucleotides can be prepared by use of  
controlled pore glass polymer supports (Sarin et al., 1988,  
Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451).

20 While antisense nucleotides complementary to the coding  
region sequence specific for the peptides and proteins of the  
current invention could be used, those complementary to the  
transcribed untranslated region are most preferred.

25 The antisense molecules can be delivered to cells that  
express the peptides and proteins of interest of the current  
invention *in vivo*, like, for example, ES cells. A number of  
methods have been developed for delivering antisense DNA or  
RNA to cells; e.g., antisense molecules can be injected  
directly into the tissue or cell derivation site, or modified  
antisense molecules, designed to target the desired cells  
30 (e.g., antisense linked to peptides or antibodies that  
specifically bind receptors or antigens expressed on the  
target cell surface) can be administered systemically.

35 However, it is sometimes difficult to achieve  
intracellular concentrations of antisense molecules that are  
sufficient to suppress translation of endogenous mRNAs.  
Therefore a preferred approach utilizes a recombinant DNA  
construct in which the antisense oligonucleotide is placed

under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base

5 pairs with the endogenous transcripts specific for the peptides and proteins of interest of the current invention and thereby prevent translation of the respective mRNAs. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an  
10 antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in  
15 the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to:  
20 the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310); the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797); the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445); the  
25 regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct, which can be introduced directly into the tissue or cell derivation site; e.g., the bone  
30 marrow. Alternatively, viral vectors can be used that selectively infect the desired tissue or cell type (e.g., viruses that infect cells of hematopoietic lineage), in which case administration may be accomplished by another route (e.g., systemically).

35 Ribozyme molecules designed to catalytically cleave mRNA transcripts specific for the peptides and proteins of interest of the current invention can also be used to prevent

translation of such mRNAs and expression of the peptides and proteins encoded by those mRNAs (see, e.g., PCT International Publication WO90/11364, published October 4, 1990; Sarver et al., 1990, *Science* 247:1222-1225). While ribozymes that 5 cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the 10 target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well-known in the art and is described more fully in Haseloff and Gerlach, 1988, *Nature*, 334:585-591. Preferably the ribozyme is engineered so that the cleavage recognition 15 site is located near the 5' end of the mRNA of interest; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as 20 the one that occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA), which has been extensively described by Thomas Cech and collaborators (Zaug et al., 1984, *Science*, 224:574-578; Zaug and Cech, 1986, *Science*, 231:470-475; Zaug et al., 1986, *Nature*, 324:429-433; 25 published International Patent Application No. WO 88/04300; Been and Cech, 1986, *Cell*, 47:207-216). The Cech-type ribozymes have an eight base pair active site that hybridizes to a target RNA sequence, whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type 30 ribozymes that target eight base-pair active site sequences that are present in the mRNAs specific for the peptides and proteins of interest of the current invention.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved 35 stability, targeting, etc.) and can be delivered to cells that express the peptides and proteins of interest of the current invention *in vivo*, like, for example, ES cells. A preferred

method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy the

5 endogenous messages specific for the peptides and proteins of interest of the current invention and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is usually required for efficiency.

10 Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene of interest specific for a peptide or protein of the current invention or its promoter using targeted homologous recombination (e.g., see Smithies et al., 1985, *Nature* 317:230-234; Thomas & Capecchi, 1987, *Cell* 51:503-512; Thompson et al., 1989 *Cell* 5:313-321, 15 each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional peptide or protein of interest of the current invention (or a completely unrelated DNA sequence), flanked by DNA homologous to the 20 endogenous sequence encoding the peptide or protein of interest of the current invention (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the peptide or protein 25 of interest of the current invention *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted endogenous sequence. Such approaches are particularly suited in the agricultural field where modifications to ES cells can be used to generate 30 animal offspring with an inactive copy of a gene encoding a peptide or protein of interest of the current invention (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be adapted for use in humans provided the recombinant DNA constructs are directly administered or 35 targeted to the required site *in vivo* using appropriate viral vectors.

Alternatively, endogenous expression of a sequence of

interest can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of said sequence (i.e., the promoter and/or enhancers) to form triple helical structures that prevent transcription of the sequence 5 of interest in target cells in the body (see generally, Helene, C. 1991, *Anticancer Drug Des.*, 6(6):569-84; Helene, C. et al., 1992, *Ann. N.Y. Acad. Sci.*, 660:27-36; and Maher, L.J., 1992, *Bioassays* 14(12):807-15).

In yet another embodiment of the invention, the activity 10 of a peptide or protein of interest of the current invention can be reduced using a "dominant negative" approach. A dominant negative approach takes advantage of the interaction of the peptides or proteins of interest with other peptides or proteins to form complexes, the formation of which is a 15 prerequisite for the peptide or protein of interest of the current invention to exert its physiological activity. To this end, constructs that encode a defective form of the peptide or protein of interest of the current invention can be used in gene therapy approaches to diminish the activity of 20 said peptide or protein of interest in appropriate target cells. Alternatively, targeted homologous recombination can be utilized to introduce such deletions or mutations into the subject's endogenous gene encoding the peptide or protein of interest of the current invention in the appropriate tissue. 25 The engineered cells will express non-functional copies of the peptide or protein of interest of the current invention, thereby downregulating its activity *in vivo*. Such engineered cells should demonstrate a diminished response to 30 physiological stimuli of the activity of the affected peptide or protein of interest of the current invention, resulting in reduction of the development or cell differentiation disorder phenotype.

35 5.7.2. RESTORATION OR INCREASE IN EXPRESSION OR ACTIVITY OF A  
PEPTIDE OR PROTEIN OF THE CURRENT INVENTION TO PROMOTE  
DEVELOPMENT OR CELL DIFFERENTIATION

With respect to an increase in the level of normal gene

expression and/or gene product activity specific for any of the peptides and proteins of interest of the current invention, the respective nucleic acid sequences can be utilized for the treatment of development and cell

5 differentiation disorders. Where the cause of the development or cell differentiation dysfunction is a defective peptide or protein of the current invention, treatment can be administered, for example, in the form of gene delivery or gene therapy. Specifically, one or more copies of a normal

10 gene or a portion of the gene that directs the production of a gene product exhibiting normal function of the appropriate peptide or protein of the current invention, may be inserted into the appropriate cells within a patient or animal subject, optionally using suitable vectors. Recombinant retroviruses

15 have been widely used in gene transfer or gene delivery experiments and even human clinical trials (see generally, Mulligan, R.C., Chapter 8, In: "Experimental Manipulation of Gene Expression", Academic Press, pp. 155-173 (1983); Coffin, J., In: "RNA Tumor Viruses", Weiss, R. et al. (eds.), Cold

20 Spring Harbor Laboratory, Vol. 2, pp. 36-38 (1985)). Other eucaryotic viruses that have been used as vectors to transduce mammalian cells include adenovirus, papilloma virus, herpes virus, adeno-associated virus, rabies virus, and the like (see generally, Sambrook et al., Molecular Cloning, Cold Spring

25 Harbor Laboratory Press, Cold Spring Harbor, New York, Vol. 3:16.1-16.89 (1989)). Alternatively, cationic or other lipids may be employed to deliver polynucleotides comprising the described GTS sequences to patients. Additionally, naked DNA comprising one or more GTS sequences, optionally modified by

30 the addition of one or more of, in operable combination and orientation, a promoter, an enhancer, a ribosome entry or ribosome binding site, and/or an in-frame translation initiation codon can be employed to deliver GTSs to a patient. Another use of the above constructs includes "naked" DNA

35 vaccines that can be introduced *in vivo* alone, or in conjunction with excipients, or microcarrier spheres, nanoparticles or other supporting or dosaging compounds or

molecules.

The gene replacement/delivery therapies described above should be capable of delivering gene sequences to the cell types within patients that express the peptide or protein of interest of the current invention. Alternatively, targeted homologous recombination can be utilized to correct the defective endogenous gene in the appropriate cell type. In animals, targeted homologous recombination can be used to correct the defect in ES cells in order to generate offspring with a corrected trait.

Finally, compounds identified in the assays described above that stimulate, enhance, or modify the activity of the peptides and proteins of the current invention can be used to achieve proper development and cell differentiation. The formulation and mode of administration will depend upon the physico-chemical properties of the compound.

#### 5.8. PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION

Compounds that are determined to affect gene expression of the peptides and proteins of the current invention, or the interaction of those peptides and proteins with any of their binding partners, can be administered to a patient at therapeutically effective doses to treat or ameliorate, or to delay the onset of, development and/or cell differentiation disorders. A therapeutically effective dose refers to that amount of the compound sufficient to result in any amelioration or retardation of disease symptoms, or development and cell differentiation or proliferation disorders.

##### 5.8.1. EFFECTIVE DOSE

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population).

The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side

5 effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

10 The data obtained from the cell culture assays and animal studies can be used in formulating a dosage range for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of 15 administration utilized. For any compound used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (i.e., the 20 concentration of the test compound that achieves a half-. maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

25 When the therapeutic treatment of disease is contemplated, the appropriate dosage may also be determined using animal studies to determine the maximal tolerable dose, or MTD, of a bioactive agent per kilogram weight of the test subject. In general, at least one animal species tested is 30 mammalian. Those skilled in the art regularly extrapolate doses for efficacy and avoiding toxicity to other species, including human. Before human studies of efficacy are undertaken, Phase I clinical studies in normal subjects help establish safe doses.

35 Additionally, the bioactive agent may be complexed with a variety of well established compounds or structures that, for instance, enhance the stability of the bioactive agent, or

otherwise enhance its pharmacological properties (e.g., increase *in vivo* half-life, reduce toxicity, etc.).

The above therapeutic agents will be administered by any number of methods known to those of ordinary skill in the art including, but not limited to, administration by inhalation; subcutaneous (sub-q), intravenous (I.V.), intraperitoneal (I.P.), intramuscular (I.M.), or intrathecal injection; or as a topically applied agent (transderm, ointments, creams, salves, eye drops, and the like).

10

#### 5.8.2. FORMULATIONS AND USE

15 Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

20 Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

25 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well-known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats);

emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The

5 preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the 10 form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, 15 e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in 20 an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or 25 continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents 30 such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated as compositions for 35 rectal administration such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. The compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention in any way whatsoever.

## 6.0. EXAMPLES

### 6.1. GENERATION OF A LIBRARY OF MUTATED MOUSE ES CELLS DEFINED BY GTS SEQUENCES

Initially, the retroviral vector VICTR 3, described in detail in U.S. application Ser. No. 08/728,963, incorporated herein by reference in its entirety, was used to generate a library of gene trapped ES cell clones. A plasmid containing the VICTR 3 cassette was constructed by conventional cloning techniques and designed to employ the features described above. Namely, the cassette contained a PGK promoter directing transcription of an exon that encodes the *puro* marker and ends in a canonical splice donor sequence. At the end of the puromycin exon, sequences were added as described that allow for the annealing of two nested PCR and sequencing primers. The vector backbone was based on pBluescript KS+ from Stratagene Corporation.

The plasmid construct was linearized by digestion with *Sca*I, which cuts at a unique site in the plasmid backbone.

The plasmid was then transfected into the mouse ES cell line AB2.2 by electroporation using a BioRad GenePulser apparatus. After the cells were allowed to recover, gene trap clones were selected by adding puromycin to the medium at a final

5 concentration of 3  $\mu$ g/ml. Positive clones were allowed to grow under selection for approximately 10 days before being removed and cultured separately for storage and to determine the sequence of the disrupted gene.

Total RNA was isolated from an aliquot of cells from each 10 of 18 gene trap clones chosen for study. Five micrograms of this RNA was used in a first strand cDNA synthesis reaction using the "RS" primer. This primer has unique sequences (for subsequent PCR) on its 5' end and nine random nucleotides or nine T (thymidine) residues on it's 3' end. Reaction products 15 from the first strand synthesis were added directly to a PCR with outer primers specific for the engineered sequences of puromycin and the "RS" primer. After amplification, aliquots of reaction products were subjected to a second round of amplification using primers internal, or nested, relative to 20 the first set of PCR primers. This second amplification provided more reaction product for sequencing and also provided increased specificity for the specifically gene trapped DNA.

The products of the nested PCR were visualized by agarose 25 gel electrophoresis, and seventeen of the eighteen clones provided at least one band that was visible on the gel with ethidium bromide staining. Most gave only a single band, which is an advantage in that a single band is generally easier to sequence. The PCR products were sequenced directly 30 after excess PCR primers and nucleotides were removed by filtration in a spin column (Centricon-100, Amicon). DNA was added directly to dye terminator sequencing reactions (purchased from ABI) using the standard M13 forward primer, a region for which was built into the end of the puro exon in 35 all of the PCR fragments.

Subsequent studies have used both VICTR 3 and VICTR 20. Like VICTR 3, VICTR 20 is exemplary of a family of vectors

that incorporate two main functional units: a sequence acquisition component having a strong promoter element (phosphoglycerate kinase 1) active in ES cells that is fused to the puromycin resistance gene coding sequence that lacks a 5 polyadenylation sequence but is followed by a synthetic consensus splice donor sequence (PGKpuroSD); and 2) a mutagenic component that incorporates a splice acceptor sequence fused to a selectable, colorimetric marker gene and followed by a polyadenylation sequence (for example, SA $\beta$ geopA 10 or SAires $\beta$ geopA). Also like VICTR 3, stop codons have been engineered into all three reading frames in the region between the 3' end of the selectable marker and the splice donor site. A diagrammatic description of structure and functions of VICTRs 3 and 20 is provided in Figure 1.

15 When VICTRs 3, 20, and various variations thereof, were used in the commercial scale application of the presently disclosed invention; many mutagenized ES cell clones were rapidly engineered and obtained. Sequence analysis obtained from these clones has identified a wide variety of both 20 previously identified and novel sequences. Each of the sequences presented in SEQ ID NOS: 1-1,000 identify heretofore unknown coding regions of mammalian genes. Moreover, given that totipotent ES cells have been targeted, each of the disclosed mutants effectively represents genetically 25 engineered animals that incorporate the mutated cells and that are preferably capable of germline transmission of the listed mutations.

The discovery potential of the presently described invention as a genomics resource becomes apparent when one 30 considers that the genes mutated/represented in the Sequence Listing were identified in a few years, whereas simply constructing the mutated cells would have taken many decades of person-hours using conventional methods of genetic manipulation such as targeted homologous recombination.

35 Additionally, and perhaps more importantly, the gene trap sequences thus far identified provide novel sequence information (see SEQ ID NOS: 1-1,000), and, because of the

functional aspects of the presently described ES cell system, the cellular and developmental functions of these novel sequences can be rapidly established.

5 The cloned 3' RACE products resulting after the target ES cells were infected with VICTR 20 were purified using conventional column chromatography (e.g., S300 and G-50 columns), and the products were recovered by centrifugation. Purified PCR products were quantified by fluorescence using PicoGreen (Molecular Probes, Inc., Eugene Oregon) as per the 10 manufacturer's instructions.

Dye terminator cycle sequencing reactions with AmpliTaq® FS DNA polymerase (Perkin Elmer Applied Biosystems, Foster City, CA) were carried out using approximately 7 pmoles of sequencing primer, and approximately 30-120 ng of 3' template. 15 Unincorporated dye terminators were removed from the completed sequencing reactions using G-50 columns as described above. The reactions were dried under vacuum, resuspended in loading buffer, and electrophoresed through a 6% Long Ranger acrylamide gel (FMC BioProducts, Rockland, ME) on an ABI 20 Prism® 377 with XL upgrade as per the manufacturer's instructions. The sequences of the resulting amplicons, or GTSSs, are described in SEQ ID NOS: 1-1,000.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various 25 modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be 30 understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention that are obvious to those skilled in the field of molecular biology or related fields are intended to be 35 within the scope of the following claims.